Dauphine S Barone

US Patent:

7122183, Oct 17, 2006

Filed:

Aug 26, 2003

Appl. No.:

10/648136

Inventors:

Kendall M. Mohler - Seattle WA, US
Dauphine S. Barone - Seattle WA, US
Jacques J. Peschon - Seattle WA, US
Mary K. Kennedy - Seattle WA, US
John D. Pluenneke - Seattle WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 39/395
C07K 21/08
C07K 16/22

US Classification:

4241331, 4241541, 4241731, 5303873, 53038823

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

7273609, Sep 25, 2007

Filed:

Aug 18, 2006

Appl. No.:

11/506645

Inventors:

Kendall M. Mohler - Poulsbo WA, US
Dauphine S. Barone - Mill Creek WA, US
Mary K. Kennedy - Seattle WA, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 39/395
C07K 21/08
C07K 16/22

US Classification:

4241331, 4241541, 4241731, 5303873, 53038823

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

8268311, Sep 18, 2012

Filed:

Sep 18, 2008

Appl. No.:

12/675013

Inventors:

Jacqueline A. Kirchner - Seattle WA, US
Kenneth A. Brasel - Seattle WA, US
Kara Olson - White Plains NY, US
Jose Carlos Escobar - Sammamish WA, US
Dauphine Barone - Mill Creek WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241331, 4241301, 4241411, 4241351, 4241421

Abstract:

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

US Patent:

8481704, Jul 9, 2013

Filed:

Aug 20, 2012

Appl. No.:

13/589935

Inventors:

Jacqueline A. Kirchner - Seattle WA, US
Kenneth A. Brasel - Seattle WA, US
Kara Olson - White Plains NY, US
Jose Carlos Escobar - Sammamish WA, US
Dauphine Barone - Mill Creek WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07H 21/04
C12P 21/08
C12N 15/10

US Classification:

536 2353, 435 691, 4353201, 435325

Abstract:

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

US Patent:

20020064527, May 30, 2002

Filed:

Aug 3, 2001

Appl. No.:

09/921667

Inventors:

Kendall Mohler - Poulsbo WA, US
Dauphine Barone - Everett WA, US
Jacques Peschon - Seattle WA, US
Mary Kennedy - Seattle WA, US
John Pluenneke - Parkville MO, US

International Classification:

A61K039/395
A61K038/17

US Classification:

424/144100, 514/012000

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF inhibitors.

US Patent:

20080213259, Sep 4, 2008

Filed:

Aug 16, 2007

Appl. No.:

11/840136

Inventors:

Kendall M. Mohler - Poulsbo WA, US
Dauphine S. Barone - Mill Creek WA, US
Jacques J. Peschon - Seattle WA, US
Mary K. Kennedy - Seattle WA, US
John D. Pluenneke - Parkville MO, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 39/395
A61K 38/16
A01K 67/00
G01N 33/00
A61P 37/00
A61P 29/00

US Classification:

4241331, 4241301, 514 12, 4241581, 4241451, 800 9, 800 3

Abstract:

The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

20100071079, Mar 18, 2010

Filed:

Nov 10, 2009

Appl. No.:

12/615619

Inventors:

Kendall M. MOHLER - Poulsbo WA, US
Dauphine S. Barone - Mill Creek WA, US
Jacques J. Peschon - Seattle WA, US
Mary K. Kennedy - Seattle WA, US
John D. Pluenneke - Parkville MO, US

Assignee:

Immunex Corporation - Thousand Oaks CA

International Classification:

A61K 49/00
A61K 38/16
A61K 39/395
A01K 67/027
A61P 37/06
A61P 19/02

US Classification:

800 3, 4241301, 514 12, 4241331, 4241451, 4241581, 800 8, 800 9

Abstract:

The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

US Patent:

20130259799, Oct 3, 2013

Filed:

Jun 11, 2013

Appl. No.:

13/914905

Inventors:

Kenneth A. Brasel - Seattle WA, US
Kara Olson - White Plains NY, US
Jose Carlos Escobar - Sammamish WA, US
Dauphine Barone - Mill Creek WA, US

International Classification:

A61K 51/00
A61K 45/06
A61K 39/395

US Classification:

424 111, 5303892, 5303873, 53038823, 536 2353, 4353201, 435335, 435 696, 4241581

Abstract:

Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.

Address:

14817 13 Dr SE, Mill Creek, WA 98012

VIN:

JNKBV61E67M711663

Make:

INFINITI

Model:

G35

Year:

2007